Hudson Holding

Hudson Therapeutics is a clinical-stage biotechnology company and the U.S. subsidiary of the South Korean firm Shaperon. The company focuses on developing novel inflammasome inhibitors that utilize a unique mechanism of action involving GPCR19-P2X7 modulation to suppress a broad spectrum of inflammatory cytokines. Its lead programs include NuGel for atopic dermatitis and NuSepin for COVID-19 pneumonia, both of which are in Phase 2 clinical trials. Hudson Therapeutics also leverages its proprietary AI-based platform, AIDEN, and its nanobody technology, NanoMab, to advance therapies for complex immune-mediated inflammatory disorders, including Alzheimer's disease and alopecia areata.